GILD

Gilead Sciences
D

GILD

114.530
USD
1.28
(1.13%)
مغلق
حجم التداول
231,958
الربح لكل سهم
8
العائد الربحي
2.76
P/E
24
حجم السوق
142,467,202,228
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 8 أشهر
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة
ABBV
ABBV
4.430
(2.33%)
194.960 USD
AMGN
AMGN
3.62
(1.22%)
300.25 USD
BIIB
BIIB
2.420
(1.82%)
135.360 USD
INCY
INCY
1.660
(2.42%)
70.330 USD
MRK
MRK
0.340
(0.41%)
84.060 USD
NVS
NVS
0.775
(0.63%)
123.715 USD
PFE
PFE
0.230
(0.90%)
25.780 USD
REGN
REGN
7.05
(1.28%)
559.63 USD
SNY
SNY
0.500
(1.02%)
49.350 USD
المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).